Labcorp has entered a new partnership with HealthVerity to bolster its end-to-end drug development and clinical trial programmes.
HealthVerity is provider of identity, privacy, governance, and exchange (IPGE) for real-world data (RWD).
The IPGE platform of HealthVerity is a combined technology and RWD infrastructure that would aid Labcorp Drug Development and other participating firms to access completely interoperable, HIPAA-compliant data from the ecosystem of health care and consumer data in the US.
Currently, study sponsors are considering RWD’s potential to produce longitudinal patient insights thorough out the trials.
With increasing predictive analytics and artificial intelligence applications needing completely interoperable RWD, Labcorp can utilise the HealthVerity IPGE platform to align de-identified patient data with ten times improved accuracy compared with available industry options.
Labcorp’s access to HealthVerity’s RWD with on-demand de-identification and data linking expertise will boost the former’s capacity to become a ‘trusted’ information source for its clients.
Labcorp Drug Development CEO Dr Paul Kirchgraber said: “This collaboration allows Labcorp to expand existing end-to-end solutions for drug and diagnostics development, commercialisation and clinical trial efforts to include large-scale access to real-world data for research applications.
“By applying advanced analytics, Labcorp can help its clients improve their processes and reach better outcomes.
“Our substantial repository of test results can also help study sponsors more quickly and accurately assess patient eligibility for clinical trials, enrol patients faster and accelerate the availability of new medicines.”
In April this year, Labcorp expanded its strategic partnership with Medidata to provide a suite of clinical trial technologies and services.
Under this alliance, Labcorp will use the technology platform of Medidata to expand the use and functionality of decentralised clinical trials and co-develop digital biomarkers.